Research programme: microRNA modulators - Mirrx Therapeutics
Alternative Names: Blockmirs for hepatitis C - Mirrx TherapeuticsLatest Information Update: 16 Jul 2016
At a glance
- Originator Stealth Biotech
- Developer Mirrx Therapeutics
- Class Antisense oligonucleotides
- Mechanism of Action Gene expression modulators; MicroRNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in Denmark
- 16 Feb 2010 Preclinical trials in Hepatitis C in Denmark (unspecified route)